

REMARKS

Applicants have added claim 125 directed to pharmaceutical compositions.

Applicants have accordingly deleted claims 71-75 directed to pharmaceutical compositions having specific intended uses. Support for added claim 125 may be found throughout the specification as originally filed (see particularly, page 113, lines 17-21) and in claims 71-75 as originally filed.

Applicants have added claims 126-128 to recite methods for administering the compounds and pharmaceutical compositions of this invention. Support for these amendments may be found throughout the specification as originally filed (see particularly, page 116, line 31 to page 117, line 12) and claim 76 as originally filed.

Applicants request consideration of the application and early allowance of the pending claims.

Respectfully submitted,



James F. Haley, Jr. (Reg. No. 27,794)

Lisa A. Dixon (Reg. No. 40,995)

Attorneys for Applicants

c/o FISH & NEAVE

1251 Avenue of the Americas

New York, New York 10020

Tel.: (212) 596-9000

Fax.: (212) 596-9090

APPENDIX

AMENDED CLAIMS MARKED TO SHOW AMENDMENTS

76. A method for treating or preventing a disease selected from the group consisting of IL-1 mediated disease, autoimmune disease, inflammatory disease, [and] neurodegenerative disease, and infectious disease in a patient comprising the step of administering to said patient a pharmaceutical composition according to [any one of claims 71-75] claim 125.

0988673-062101  
TOT290-E498860